Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, October 30, 2014
 
Register | Sign in
Home Page > White Papers
  White Papers
Scientific News
Accelerating Spirocyclic Polyketide Synthesis
Powerful flow chemistry techniques used for complex multi-stage synthesis of spirocyclic polyketides.
MS Drug Candidate Shows Promise for Ulcerative Colitis
Positive new clinical data were released today on a drug candidate for ulcerative colitis that was first discovered and synthesized at The Scripps Research Institute.
First Atlas of Body Clock Gene Expression in Mammals Informs Timing of Drug Delivery
Penn Medicine study has implications for 100 top-selling US drugs, half of which target daily-oscillating genes.
New Technique has Profound Implications for Drug Development
The method, developed by Scripps Research Institute chemists, expands options for making pure batches of ‘one-handed’ molecules.
Blood Test Developed to Diagnose Early Onset Alzheimer’s Disease
New blood-test could predict a person’s risk of developing AD much earlier than is currently possible.
Tea and Citrus Products Could Lower Ovarian Cancer Risk
New UEA research finds that women who consume foods containing flavonols and flavanones significantly decrease their risk of developing epithelial ovarian cancer.
TxCell Achieves Positive Results for Col-Treg in a Model of Autoimmune Uveitis
TxCell set for phase I/II proof of principle clinical study in Q2 2015 for its second therapeutic candidate in this rare eye disease.
Heart Drug May Help Treat ALS, Mouse Study Shows
Scientists blocked the enzyme in ALS astrocytes using digoxin, a medication used in the treatment of heart failure.
Team Discovers How Microbes Build a Powerful Antibiotic
Researchers discovery opens up new avenues of research into thousands of similar molecules.
LLNL, UC Davis Partner to Personalize Cancer Medications
With a $7.8 million, five-year grant from the NIH researchers are utilizing accelerator mass spectrometry for cancer research.
Scroll Up
Scroll Down

Dawn of a New Era for Kinase Drug Discovery: Kinome Wide Profiling and Screening Solutions Coupled to Functional Cell-based Assays Enable Launch of Selective and Functional Kinase Inhibitors
Bookmark and Share
DiscoveRx Corporation


For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



Validation of Drug Toxicity Prediction using DiscoveRx Model
BioMAP® Systems was shown to identify important safety aspects of drugs and chemicals more efficiently and accurately than can be achieved by animal testing.
Tuesday, May 20, 2014
DiscoveRx Corporation Acquires Bioseek
DiscoveRx adds primary cell assays to its portfolio of drug discovery solutions.
Thursday, November 08, 2012
DiscoveRx Corporation Continues to Innovate with Solutions for Epigenetic Drug Discovery Programs
The company announced availability of platform for studying Bromodomains, an emerging class of epigenetic targets.
Monday, February 06, 2012
DiscoveRx Expands its GPCR Technology Portfolio to Include Advanced Technologies
Introduces two additional GPCR platforms to facilitate counterscreening, lead optimization and SAR evaluation of compounds.
Friday, April 09, 2010
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv